MERS-CoV: a global challenge
Identifieur interne : 000844 ( Pmc/Corpus ); précédent : 000843; suivant : 000845MERS-CoV: a global challenge
Auteurs :Source :
- Lancet (London, England) [ 0140-6736 ] ; 2013.
Url:
DOI: 10.1016/S0140-6736(13)61184-8
PubMed: 23746882
PubMed Central: 7137988
Links to Exploration step
PMC:7137988Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MERS-CoV: a global challenge</title></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23746882</idno><idno type="pmc">7137988</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137988</idno><idno type="RBID">PMC:7137988</idno><idno type="doi">10.1016/S0140-6736(13)61184-8</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000844</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000844</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">MERS-CoV: a global challenge</title></analytic><series><title level="j">Lancet (London, England)</title><idno type="ISSN">0140-6736</idno><idno type="eISSN">1474-547X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pmc article-type="editorial"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet</journal-id><journal-id journal-id-type="iso-abbrev">Lancet</journal-id><journal-title-group><journal-title>Lancet (London, England)</journal-title></journal-title-group><issn pub-type="ppub">0140-6736</issn><issn pub-type="epub">1474-547X</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23746882</article-id><article-id pub-id-type="pmc">7137988</article-id><article-id pub-id-type="publisher-id">S0140-6736(13)61184-8</article-id><article-id pub-id-type="doi">10.1016/S0140-6736(13)61184-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>MERS-CoV: a global challenge</article-title></title-group><contrib-group><contrib contrib-type="author" id="au10"><name><surname>The Lancet</surname></name></contrib></contrib-group><pub-date pub-type="pmc-release"><day>7</day><month>6</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub" iso-8601-date="2013-06-14"><season>8-14 June</season><year>2013</year></pub-date><pub-date pub-type="epub"><day>7</day><month>6</month><year>2013</year></pub-date><volume>381</volume><issue>9882</issue><fpage>1960</fpage><lpage>1960</lpage><permissions><copyright-statement>Copyright © 2013 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="para10">In her closing remarks at the World Health Assembly in Geneva last week, WHO's Director-General Margaret Chan announced that the new Middle East Respiratory Syndrome coronavirus (MERS-CoV) was her present “greatest concern”.</p><p id="para20">What do we know about MERS-CoV? The novel virus was first reported in September, 2012, in a patient in Saudi Arabia. As of June 2, WHO has been informed of 53 laboratory-confirmed cases of infection, including 30 deaths. Most cases have arisen in the Middle East (Saudi Arabia, Qatar, Jordan, and the United Arab Emirates), with a smaller number of cases present elsewhere (Tunisia, Germany, UK, France, and Italy)—either related to travellers returning from the region or transferred to the country for care. Common symptoms in patients are acute, serious respiratory illness with fever, cough, shortness of breath, and breathing difficulties. Many of those infected develop severe pneumonia.</p><p id="para30">There have been small clusters of infection in several countries suggesting that person-to-person transmission is possible when close contact occurs. But there is no evidence of sustained transmission. Last week, a <italic>Lancet</italic><ext-link ext-link-type="uri" xlink:href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60982-4/fulltext" id="interrefs10">Article</ext-link> showed that the virus's incubation could be longer than previously reported—9–12 days instead of 1–9 days—which has implications for length of quarantine needed to prevent secondary cases.</p><p id="para40">Many unanswered questions remain about MERS-CoV, including the source of, and main risk factors for, infection. A collaborative global research effort will help close the gaps in knowledge. In this regard, news that the scientists at Erasmus Medical Centre, Netherlands, who first identified the virus, have applied for a patent on virus data has caused consternation. The researchers have publicly responded to say that they have sent the virus free of charge to many public research and health institutions and they will continue to do so. They have told media that they applied for a patent to ensure companies invest in making diagnostics, vaccines, and antiviral medication. Let us hope their expectations prove correct.</p><p id="para50">Free information sharing, trust, and research cooperation will be crucial to aid prevention, diagnosis, and treatment of this evolving global health threat.</p><p id="para60"><fig id="f10"><graphic xlink:href="fx1_lrg"></graphic><permissions><copyright-statement>© 2013 Centre For Infections/Public Health England/Science Photo Library</copyright-statement><copyright-year>2013</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></fig></p></body></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000844 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000844 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7137988
|texte= MERS-CoV: a global challenge
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23746882" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |